Updated: LHA Life Sciences & Medical Technologies Virtual Conference

NEW YORK, June 27, 2012 /PRNewswire/ --

Thursday, June 28, 2012

The event will feature 30-minute corporate presentations with accompanying slides by executives from seven industry leaders.

Presentations begin at 9:00 a.m. Eastern Time and can be accessed at http://www.informedinvestors.com. Individual presentations also will be available at each presenting company's website.

We hope you can join us.

If you cannot attend the live event, presentations will be archived at http://www.informedinvestors.com and at each presenting company's website for approximately 90 days. If you have any questions, please call Carolyn Curran at (212) 838-3777 or ccurran@lhai.com.

LHA is a leading independent investor relations firm. As IR specialists with more than 25 years of experience, we partner with public and soon-to-be public companies to create and support best practices investor and media relations programs. By focusing on the development of public company identity and the communication of strategic vision, we build awareness, enthusiasm and sponsorship among target audiences in the investment community to maximize valuation. Our programs deliver measurable results so clients can assess the impact of their investor relations initiatives.

LHA Life Sciences & Medical Technologies Virtual ConferenceJune 28, 2012 beginning at 9:00 a.m. Eastern Time

9:00 a.m. Eastern TimeCAS Medical Systems is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. Direct monitoring of tissue oxygenation provides a unique and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates. For additional information please visit http://www.casmed.com.

9:30 a.m. Eastern TimeChembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For additional information please visit http://www.chembio.com.

Read the rest here:
Updated: LHA Life Sciences & Medical Technologies Virtual Conference